How quickly did patients <br class="visible-xs">experience itch relief for their <br class="visible-xs">prurigo nodularis?

Itch reduction (as measured by the proportion of patients with a ≥4-point improvement in WI-NRS) was the primary endpoint in two 24-week randomized, double-blind, placebo-controlled, multicenter, parallel-group studies (PRIME and PRIME2). In the PRIME trial, a nominal difference was observed at Week 4 (19% with DUPIXENT vs 4% with placebo; P=0.0066), with significant improvement at Week 24.^1,2

In PRIME, the proportion of DUPIXENT patients who achieved ≥4-point improvement in WI-NRS was ≈3 times more than placebo at Week 24 (60% with DUPIXENT vs 18% with placebo; P<0.0001)^1,2

Definitive conclusions cannot be made for results earlier than at 24 weeks in PRIME. Data were not multiplicity controlled.

PRIME2

37% of DUPIXENT patients achieved a meaningful response at Week 12 vs 22% with placebo; P=0.0216 [primary endpoint]. At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo; P<0.0001 [secondary endpoint]^1,2

REVIEW WI-NRS RESULTS